To evaluate adverse events (AEs) associated with teprotumumab in the reatment of thyroid eye disease (TED).MethodsReports involving teprotumumab were extracted from the U.S.FDA Adverse Event Reporting System (FAERS) from the first quarter of 2020 to the first quarter of 2025....
✦ Clinical Takeaway ✦
Audiologists should be aware that teprotumumab is associated with hearing-related adverse events in post-marketing data; patients on this drug warrant audiological monitoring, though causality and rates require further prospective study.
✦ Why It Matters ✦
As teprotumumab use grows in thyroid eye disease management, audiologists may increasingly encounter referred patients with drug-related hearing complications, reinforcing the need for ototoxicity monitoring protocols.
✦ Key Points ✦
- 01Disproportionality analysis of FDA FAERS data covering 5 years of teprotumumab post-marketing surveillance.
- 02